Neuren Pharmaceuticals (ASX:NEU) has reported a strong first-half performance for 2025, nearly doubling its profit after tax as royalties from its Rett syndrome therapy DAYBUE (trofinetide) continue to climb and its second drug candidate NNZ-2591 advances through late-stage development. …
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics secures Chinese patent to boost immune cell function in solid tumours
August 27, 2025 - - Australian Biotech -
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 - - Australian Biotech -
Starpharma advances dendrimer platform with clinical, commercial, and strategic progress
August 27, 2025 - - Australian Biotech -
Biome achieves breakthrough year with first profit and rapid global expansion
August 27, 2025 - - Australian Biotech -
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 - - Australian Biotech -
Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger
August 27, 2025 - - Latest News -
Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push
August 27, 2025 - - Latest News